Genmab Historical Balance Sheet

GMAB Stock

USD 19.76 0.08 0.40%

Trend analysis of Genmab AS balance sheet accounts such as Other Current Liabilities of 3.7 B or Total Current Liabilities of 5.6 B provides information on Genmab AS's total assets, liabilities, and equity, which is the actual value of Genmab AS to its prevalent stockholders. By breaking down trends over time using Genmab AS balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Genmab AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Genmab AS is a good buy for the upcoming year.

Genmab AS Inventory

65.1 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

About Genmab Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Genmab AS at a specified time, usually calculated after every quarter, six months, or one year. Genmab AS Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Genmab AS and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Genmab currently owns. An asset can also be divided into two categories, current and non-current.

Genmab AS Balance Sheet Chart

At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 1.1 B, whereas Current Deferred Revenue is forecasted to decline to about 22.8 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Genmab AS assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Genmab AS books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Genmab AS balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Genmab AS are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Genmab AS's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Genmab AS current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 1.1 B, whereas Current Deferred Revenue is forecasted to decline to about 22.8 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	1.8B	2.5B	5.3B	5.6B
Other Current Liabilities	1.7B	2.3B	3.5B	3.7B

Total Current Liabilities Other Current Liab

Genmab AS balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments
Total Assets		0.99	0.98	0.9	1.0	0.99	-0.35	-0.89	0.99	0.93	0.92	0.82	0.82	0.94	0.52	-0.78	0.9	-0.03	0.69	0.9	0.98	0.96	0.91	0.75	0.56	0.93
Short Long Term Debt Total	0.99		0.99	0.94	0.97	0.99	-0.23	-0.87	0.98	0.96	0.9	0.85	0.86	0.9	0.43	-0.76	0.93	-0.08	0.61	0.94	0.99	0.93	0.92	0.79	0.48	0.88
Other Current Liab	0.98	0.99		0.95	0.97	0.98	-0.3	-0.83	0.97	0.96	0.86	0.89	0.9	0.87	0.44	-0.73	0.95	-0.02	0.59	0.95	0.98	0.9	0.88	0.84	0.49	0.86
Total Current Liabilities	0.9	0.94	0.95		0.86	0.9	-0.08	-0.67	0.88	0.91	0.71	0.96	0.97	0.71	0.33	-0.61	0.99	-0.11	0.41	1.0	0.91	0.75	0.79	0.93	0.38	0.69
Total Stockholder Equity	1.0	0.97	0.97	0.86		0.99	-0.39	-0.92	0.99	0.92	0.94	0.77	0.77	0.96	0.54	-0.79	0.86	-0.01	0.73	0.86	0.98	0.98	0.92	0.69	0.58	0.96
Property Plant And Equipment Net	0.99	0.99	0.98	0.9	0.99		-0.28	-0.92	0.99	0.95	0.94	0.79	0.81	0.94	0.46	-0.79	0.89	-0.08	0.65	0.9	1.0	0.96	0.91	0.72	0.5	0.92
Current Deferred Revenue	-0.35	-0.23	-0.3	-0.08	-0.39	-0.28		0.29	-0.35	-0.24	-0.29	-0.17	-0.12	-0.38	-0.34	0.34	-0.13	-0.51	-0.46	-0.1	-0.24	-0.39	-0.24	-0.13	-0.34	-0.48
Net Debt	-0.89	-0.87	-0.83	-0.67	-0.92	-0.92	0.29		-0.91	-0.81	-1.0	-0.5	-0.53	-0.99	-0.54	0.82	-0.65	0.05	-0.79	-0.66	-0.9	-0.97	-0.87	-0.4	-0.56	-0.95
Retained Earnings	0.99	0.98	0.97	0.88	0.99	0.99	-0.35	-0.91		0.94	0.93	0.8	0.8	0.94	0.44	-0.8	0.88	-0.06	0.65	0.88	0.99	0.96	0.91	0.72	0.48	0.92
Accounts Payable	0.93	0.96	0.96	0.91	0.92	0.95	-0.24	-0.81	0.94		0.84	0.81	0.85	0.84	0.37	-0.7	0.88	0.03	0.53	0.9	0.96	0.87	0.86	0.76	0.41	0.82
Cash	0.92	0.9	0.86	0.71	0.94	0.94	-0.29	-1.0	0.93	0.84		0.56	0.58	0.99	0.52	-0.82	0.7	-0.05	0.77	0.71	0.92	0.98	0.89	0.46	0.55	0.96
Non Current Assets Total	0.82	0.85	0.89	0.96	0.77	0.79	-0.17	-0.5	0.8	0.81	0.56		0.99	0.57	0.27	-0.49	0.98	-0.09	0.3	0.97	0.81	0.62	0.68	0.99	0.32	0.57
Non Currrent Assets Other	0.82	0.86	0.9	0.97	0.77	0.81	-0.12	-0.53	0.8	0.85	0.58	0.99		0.58	0.24	-0.47	0.97	-0.12	0.27	0.97	0.83	0.63	0.7	0.98	0.29	0.56
Cash And Short Term Investments	0.94	0.9	0.87	0.71	0.96	0.94	-0.38	-0.99	0.94	0.84	0.99	0.57	0.58		0.6	-0.8	0.7	0.0	0.82	0.71	0.92	1.0	0.89	0.47	0.63	0.99
Common Stock Total Equity	0.52	0.43	0.44	0.33	0.54	0.46	-0.34	-0.54	0.44	0.37	0.52	0.27	0.24	0.6		-0.23	0.32	0.07	0.9	0.33	0.44	0.58	0.49	0.21	1.0	0.64
Common Stock Shares Outstanding	-0.78	-0.76	-0.73	-0.61	-0.79	-0.79	0.34	0.82	-0.8	-0.7	-0.82	-0.49	-0.47	-0.8	-0.23		-0.6	-0.3	-0.61	-0.61	-0.76	-0.82	-0.72	-0.41	-0.26	-0.78
Non Current Liabilities Total	0.9	0.93	0.95	0.99	0.86	0.89	-0.13	-0.65	0.88	0.88	0.7	0.98	0.97	0.7	0.32	-0.6		-0.14	0.4	1.0	0.9	0.74	0.78	0.95	0.37	0.68
Other Current Assets	-0.03	-0.08	-0.02	-0.11	-0.01	-0.08	-0.51	0.05	-0.06	0.03	-0.05	-0.09	-0.12	0.0	0.07	-0.3	-0.14		0.21	-0.12	-0.11	0.01	-0.08	-0.09	0.07	0.05
Other Stockholder Equity	0.69	0.61	0.59	0.41	0.73	0.65	-0.46	-0.79	0.65	0.53	0.77	0.3	0.27	0.82	0.9	-0.61	0.4	0.21		0.41	0.62	0.8	0.67	0.2	0.9	0.85
Total Liab	0.9	0.94	0.95	1.0	0.86	0.9	-0.1	-0.66	0.88	0.9	0.71	0.97	0.97	0.71	0.33	-0.61	1.0	-0.12	0.41		0.91	0.75	0.79	0.94	0.38	0.69
Property Plant And Equipment Gross	0.98	0.99	0.98	0.91	0.98	1.0	-0.24	-0.9	0.99	0.96	0.92	0.81	0.83	0.92	0.44	-0.76	0.9	-0.11	0.62	0.91		0.94	0.91	0.74	0.48	0.9
Total Current Assets	0.96	0.93	0.9	0.75	0.98	0.96	-0.39	-0.97	0.96	0.87	0.98	0.62	0.63	1.0	0.58	-0.82	0.74	0.01	0.8	0.75	0.94		0.91	0.53	0.61	0.99
Short Term Debt	0.91	0.92	0.88	0.79	0.92	0.91	-0.24	-0.87	0.91	0.86	0.89	0.68	0.7	0.89	0.49	-0.72	0.78	-0.08	0.67	0.79	0.91	0.91		0.61	0.52	0.88
Intangible Assets	0.75	0.79	0.84	0.93	0.69	0.72	-0.13	-0.4	0.72	0.76	0.46	0.99	0.98	0.47	0.21	-0.41	0.95	-0.09	0.2	0.94	0.74	0.53	0.61		0.26	0.47
Common Stock	0.56	0.48	0.49	0.38	0.58	0.5	-0.34	-0.56	0.48	0.41	0.55	0.32	0.29	0.63	1.0	-0.26	0.37	0.07	0.9	0.38	0.48	0.61	0.52	0.26		0.67
Short Term Investments	0.93	0.88	0.86	0.69	0.96	0.92	-0.48	-0.95	0.92	0.82	0.96	0.57	0.56	0.99	0.64	-0.78	0.68	0.05	0.85	0.69	0.9	0.99	0.88	0.47	0.67

Click cells to compare fundamentals

Genmab AS Account Relationship Matchups

Genmab AS balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	21.1B	24.6B	30.3B	35.3B	45.8B	48.1B
Short Long Term Debt Total	319M	425M	597M	770M	1.0B	1.1B
Other Current Liab	1.1B	1.2B	1.7B	2.3B	3.5B	3.7B
Total Current Liabilities	1.3B	1.6B	1.8B	2.5B	5.3B	5.6B
Total Stockholder Equity	19.1B	22.2B	27.4B	31.6B	36.7B	38.5B
Property Plant And Equipment Net	736M	975M	1.3B	1.6B	1.9B	2.0B
Net Debt	(6.9B)	(8.5B)	(9.3B)	(14.1B)	(8.8B)	(8.4B)
Retained Earnings	7.1B	10.0B	15.0B	19.0B	23.6B	24.7B
Accounts Payable	145M	350M	1.7B	2.3B	2.7B	2.8B
Cash	7.3B	9.0B	9.9B	14.9B	9.9B	10.4B
Non Current Assets Total	2.4B	1.9B	1.9B	2.2B	18.0B	18.9B
Non Currrent Assets Other	20M	27M	48M	274M	960M	1.0B
Cash And Short Term Investments	16.1B	19.3B	22.3B	28.1B	21.1B	22.2B
Common Stock Shares Outstanding	65.9M	66.0M	66.0M	65.9M	64.6M	61.4M
Liabilities And Stockholders Equity	21.1B	24.6B	30.3B	35.3B	45.8B	48.1B
Non Current Liabilities Total	769M	863M	1.0B	1.2B	3.8B	4.0B
Other Current Assets	249M	31M	143M	101M	116.2M	110.3M
Other Stockholder Equity	11.9B	12.0B	12.2B	12.5B	12.6B	7.8B
Total Liab	2.0B	2.4B	2.8B	3.7B	9.1B	9.6B
Property Plant And Equipment Gross	736M	1.3B	1.8B	2.3B	2.7B	2.9B
Total Current Assets	18.8B	22.7B	28.4B	33.1B	27.9B	29.2B
Short Term Debt	42M	62M	74M	90M	92M	96.6M
Intangible Assets	338M	254M	146M	101M	12.3B	13.0B
Short Term Investments	8.8B	10.4B	12.4B	13.3B	11.2B	11.8B
Net Receivables	2.5B	3.4B	5.7B	4.9B	6.6B	6.9B
Inventory	(249M)	(31M)	(143M)	57M	62M	65.1M
Accumulated Other Comprehensive Income	98M	54M	81M	60M	490M	514.5M
Net Tangible Assets	13.6B	18.8B	21.9B	27.3B	31.4B	33.0B
Other Assets	150M	197M	291M	300M	345M	243.7M
Capital Lease Obligations	319M	425M	597M	770M	1.0B	1.1B
Long Term Investments	1.1B	371M	133M	134M	228M	230.6M
Property Plant Equipment	414M	736M	975M	1.3B	1.5B	1.6B
Net Invested Capital	19.1B	22.2B	27.4B	31.6B	36.7B	22.7B
Net Working Capital	17.5B	21.2B	26.6B	30.7B	22.5B	19.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:

How To Invest In Genmab

Details

Is Genmab Stock a good investment?

Details

What is Genmab AS's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

4.634

Earnings Share

1.78

Revenue Per Share

33.5366

Quarterly Revenue Growth

0.353

Return On Assets

0.1091

The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Genmab Historical Balance Sheet

Genmab AS Inventory

65.1 Million

About Genmab Balance Sheet Analysis

Genmab AS Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Genmab AS balance sheet Correlations

Genmab AS Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Genmab AS balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Total Current Assets	- 0.97	Net Debt
Short Term Investments	- 0.95	Net Debt
Net Debt	- 0.92	Property Plant And Equipment Net
Net Debt	- 0.92	Total Stockholder Equity